Earlier this month, our Senior Director and Program Team Lead, Shelley Ackerman, Ph.D., presented the advantages of next-generation #ISACs at World ADC Event Series San Diego conference! #TeamBolt #CancerResearch #Immunooncology
关于我们
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody? Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.
- 网站
-
https://boltbio.com/
Bolt Biotherapeutics, Inc. 的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- REDWOOD CITY，California
- 类型
- 上市公司
- 创立
- 2015
地点
-
主要
获取路线
900 CHESAPEAKE DRIVE
US，California，REDWOOD CITY，94063
Bolt Biotherapeutics, Inc. 员工
动态
-
Today #BoltBio reported financial results for the third quarter and provided corporate updates.?Learn more: https://bit.ly/4fqJ7sQ
-
-
Our team is attending the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting and will present updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose-escalation trial of BDC-1001. Learn more: https://bit.ly/4enqLrc #SITC24 #ImmunoOncology #CancerResearch
-
-
Our next-generation Boltbody? #ISAC program, BDC-4182, consists of a Claudin 18.2-targeting antibody that is covalently attached to a toll-like receptor (TLR) 7/8 agonist via a non-cleavable linker.??? ?? TLR7 and TLR8 are located within immune cells and play a crucial role in the body’s immune system by helping it to recognize and eliminate pathogens. TLR7 and TLR8 are expressed in a variety of immune cells capable of killing tumor cells and stimulating T cell-mediated anti-tumor responses, including:? ? ● Plasmacytoid dendritic cells (TLR7)?? ● Conventional dendritic cells (TLR7 & TLR8)?? ● Monocytes (TLR7 & TLR8)?? ● Macrophages (TLR7 & TLR8)?? ● Neutrophils (TLR8)?? ?? In pre-clinical models, BDC-4182 has demonstrated potent anti-tumor activity,?induction of T cell-dependent immunological memory, and an acceptable safety profile.?? Learn more about our science: https://bit.ly/3VunkZR??
-
-
BDC-4182 is our next-generation Boltbody? #ISAC program targeting Claudin18.2. Swipe to learn more about how this ISAC works. #ImmunoOncology #CancerResearch
-
Our first-in-class agonist antibody program, BDC-3042, targets the Dectin-2 receptor on tumor-associated macrophages (TAMs) to stimulate anti-tumor immunity.?? ? Dectin-2 is an immune-activating pattern recognition receptor that recognizes and induces protective immune responses against fungi and other microbes. It is expressed by TAMs in a broad range of solid tumors, making it an attractive target to enhance anti-tumor immunity through TAM reprogramming. ?? We’ve recently advanced to cohort 6 in our Phase 1 study of BDC-3042 in patients with advanced cancers. Learn more: https://bit.ly/3VunkZR?
-
-
#BoltBio CEO Willie Quinn shares advice and key takeaways four months into his new role. He discusses decision-making, relationship-building, and #leadership.?Read his insights below.?
Sharing a few thoughts on leadership after my first few months as Bolt CEO
-
September 24th is #WorldCancerResearchDay! Our talented team at #BoltBio is dedicated to the discovery and development of transformative treatments that leverage the immune system for a better way to treat cancer. Learn more about our science: https://bit.ly/3VunkZR??
-
-
Our next-generation Boltbody? ISAC Program, BDC-4182, consists of a Claudin 18.2-targeting antibody that is covalently attached to a novel toll-like receptor (TLR) 7/8 agonist via a non-cleavable linker.? ? Claudin 18.2 is a tight junction protein with expression restricted to the gastric mucosal epithelial cells. As these cells turn malignant, Claudin 18.2 becomes accessible on the tumor-cell surface enabling recognition and binding by BDC- 4182.?? ? This expression pattern makes it an excellent target for immune stimulating antibody conjugates (ISACs), which combine the specificity of a tumor-targeting antibody with potent immune stimulation.?This approach can target tumors with low Claudin 18.2 expression and lead to long-lasting immunological memory. ? Learn more about our science:??https://bit.ly/3VunkZR?
-
-
Meet with #BoltBio management at the Morgan Stanley 22nd Annual Global Healthcare Conference and the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference next month. We look forward to seeing you. Learn more: https://bit.ly/4g6CgWn
-